Navigation Links
Bevacizumab (Avastin) fails to improve survival for newly diagnosed glioblastoma patients
Date:2/19/2014

BALTIMORE February 19, 2014. Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

"We didn't see an improvement in overall survival or a statistically significant increase in progression-free survival, as defined in the context of this trial," says the study's senior author, Minesh P. Mehta, M.B., Ch.B., Professor of Radiation Oncology at the University of Maryland School of Medicine and a radiation oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

The U.S. Food and Drug Administration (FDA) has approved the use of bevacizumab to treat recurrent glioblastoma. Researchers sought to learn whether the drug could be beneficial as a first-line treatment.

The Phase III clinical trial, conducted by the Radiation Therapy Oncology Group (RTOG), randomized 637 patients at multiple centers, including the University of Maryland Greenebaum Cancer Center, into two groups.

Patients who received the standard treatment, plus a placebo, had a median survival of 16.1 months compared to 15.7 months for those who received the standard treatment plus bevacizumab. Although it took slightly longer for the cancer to progress in patients receiving bevacizumab (10.7 months vs. 7.3 months), the rate of progression-free survival did not meet pre-specified criteria to be statistically meaningful, according to Dr. Mehta.

Dr. Mehta, who chairs the RTOG's brain tumor committee, says researchers also found an increase in symptoms among patients who took bevacizumab, compared to a placebo. "We observed higher rates of neurocognitive decline, increased symptom burden and a decline in health-related quality of life over time among non-progressing patients treated with bevacizumab," he says. Bevacizumab's side effects include vascular problems such as hypertension, protein in urine and bleeding.

Dr. Mehta says the cognitive decline may have stemmed from unrecognized progression of the cancer, masked by the use of bevacizumab, or neurotoxicity related to the bevacizumab.

Glioblastoma is the most common and deadliest of malignant primary brain tumors in adults. It strikes two to three out of 100,000 people every year in the United States and Europe. Standard treatment is surgery, followed by radiation therapy and chemotherapy with temozolomide. Even with treatment, the average survival is approximately only 16 months. Few patients survive beyond five years. This cancer is characterized by the growth of new blood vessels, known as angiogenesis. Bevacizumab, a monoclonal antibody, is an angiogenesis inhibitor that targets a chemical signal, vascular endothelial growth factor A (VEGF-A).

The study, which was led by principal investigator Mark Gilbert, M.D., a neuro-oncologist at The University of Texas M.D. Anderson Cancer Center, was sponsored by the National Cancer Institute (NCI) (U10 CA21661 and U10 CA37422). Genentech provided additional support through an educational grant.

E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and dean of the University of Maryland School of Medicine, says, "Although researchers found that bevacizumab did not improve survival for patients newly diagnosed with glioblastoma, large-scale clinical studies such as this provide scientists with very valuable information and lay the groundwork for future research. Patients with glioblastoma have very few treatment options, and we need to continue our search for new ways to attack this very aggressive cancer."

Dr. Mehta notes that angiogenesis inhibitors, such as bevacizumab, have shown great promise in the treatment of cancer, but this study offers some perspective. "Anti-angiogenic agents are not going to be a cure-all for every cancer. They will probably have a role in several malignancies but not necessarily every one," he says.

Results of this study were reported in part at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago in June 2013.


'/>"/>

Contact: Karen Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert

Related medicine news :

1. Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer promising
2. Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
3. Brain cancer survival improved following FDA approval of bevacizumab, Mayo study finds
4. Test helps target glioblastoma patients most likely to benefit from bevacizumab
5. Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
6. Study finds glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life
7. Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
8. In-Depth Health Claim Review Saves Client Up to $15,000 on Surgery that Fails to Meet Standards for Medical Necessity
9. Mayo-led study: Drug fails to reduce diarrhea in patients receiving radiation therapy
10. Study Says Using the da Vinci Surgical Robot for a Hysterectomy Fails to Cut Complications and May Raise Pneumonia Risk, Notes Parker Waichman LLP
11. Cosmetic surgery to look whiter fails to boost womens self-esteem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: